----item----
version: 1
id: {21C7B6F9-4706-42F8-BE43-1CDB26488F94}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/03/Portola to raise $100m for final Factor Xa inhibitor antidote push
parent: {67454E32-12CF-4865-97B8-E6AB86442A6F}
name: Portola to raise $100m for final Factor Xa inhibitor antidote push
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 11df3cd0-8b26-4432-aaf4-c3eb2d3bf25c

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{B3122C5E-FF3F-438A-9C93-1B54DC1286A5}|{9557EF58-727F-4007-9C73-6232F381DFF1}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 67

Portola to raise $100m for final Factor Xa inhibitor antidote push 
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 66

Portola to raise $100m for final Factor Xa inhibitor antidote push
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 841

<p>Portola Pharmaceuticals has priced its public offering of just under 2.5 million shares at $40.00 each, with a 30-day option for an additional 374,348 shares at the same price. The offering is expected to close on 13 March. Earlier this month, Portola reported positive full data of its Phase III ANNEXA-R study which evaluated its Factor Xa inhibitor antidote andexanet alfa with Factor Xa inhibitor Xarelto (rivaroxaban). Portola plans to submit the data as part of BLA to the US FDA by the end of this year. Portola, based in South San Francisco, followed <a href="http://www.scripintelligence.com/researchdevelopment/Portolas-Factor-Xa-antidote-has-first-Phase-III-breakthrough-354249" target="_new">the initial data</a> from the study with an offering of 6.2m shares priced at $26 each for gross proceeds of $161.2m last year.</p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 696

<p>Portola Pharmaceuticals has priced its public offering of just under 2.5 million shares at $40.00 each, with a 30-day option for an additional 374,348 shares at the same price. The offering is expected to close on 13 March. Earlier this month, Portola reported positive full data of its Phase III ANNEXA-R study which evaluated its Factor Xa inhibitor antidote andexanet alfa with Factor Xa inhibitor Xarelto (rivaroxaban). Portola plans to submit the data as part of BLA to the US FDA by the end of this year. Portola, based in South San Francisco, followed <a>the initial data</a> from the study with an offering of 6.2m shares priced at $26 each for gross proceeds of $161.2m last year.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 66

Portola to raise $100m for final Factor Xa inhibitor antidote push
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150903T170000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150903T170000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150903T170000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028070
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 67

Portola to raise $100m for final Factor Xa inhibitor antidote push 
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{20E0B55E-5592-4DBF-A9D4-58B471A17E67}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357140
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042308Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

11df3cd0-8b26-4432-aaf4-c3eb2d3bf25c
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042308Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
